Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD) (NCT00097526) | Clinical Trial Compass
CompletedNot Applicable
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
125 participantsStarted 2000-04
Plain-language summary
This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.
Who can participate
Age range17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan
* Previous enrollment in the NCGS core study, 85-036
* Tanner Stage 4 or greater
* Either spontaneous or induced puberty
* Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height
Exclusion Criteria:
* Current therapy with a non Genentech GH product
* Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)
* Bilateral hip replacement
* Weight \>130 kg (286 lb.)